Our Approach

NextPoint is launching a new world of precision immuno-oncology and tumor-targeting therapeutics through its leading scientific work on the novel B7-H7/HHLA2 axis. Our innovative approach integrates foundational science with a defined clinical biomarker to identify the right patient population for each B7-H7-directed therapy, so that we can deliver a new class of monotherapies for patients including those who do not benefit from PD-1/L1 inhibitors. Our team of proven drug developers is simultaneously advancing therapeutic approaches blocking the B7-H7 immune signaling pathway and utilizing the unique upregulation of B7-H7 in cancer as an anchor for tumor-targeting treatment modalities.


B7-H7/HHLA2 is an Exciting New Target

Immunotherapies targeting the B7 receptor family such as PD-1, PD-L1, and CTLA-4 have improved outcomes for many patients and have revolutionized oncology treatment over the past two decades. B7-H7, also know as HHLA2, is a B7 family member whose inhibitory receptor, KIR3DL3, has been recently identified by our co-founders.

  • B7-H7  is expressed independently of PD-L1 and acts through 1) a unique inhibitory receptor, KIR3DL3 to block T/NK cell activation and 2) a unique stimulatory receptor, TMIGD2, to increase T and NK cell activation. 
  • The upregulation of B7-H7 expression in tumor tissues makes it an ideal tumor-targeting antigen for many different therapeutic payloads in oncology.
  • The selective expression of B7-H7 in tumor cells enables a biomarker strategy to select patients most likely to benefit from these targeted therapeutic approaches.


B7-H7/HHLA2 - A Novel Immuno-Oncology Checkpoint

Immune escape is important for tumor survival. Mechanisms of tumor immune escape can be targeted with therapeutic agents. The B7-H7 immune signaling pathway that NextPoint targets shares similarities with the PD-L1 pathway but is independently expressed and regulated.
B7-H7 inhibits activation of T and NK cells via KIR3DL3. Tumors expressing B7-H7 suppress T and NK cells within the tumor. Therefore, blocking B7-H7-KIR3DL3 interaction to enhance the anti-tumor immune response is an attractive strategy for cancer treatment. B7-H7 has also been shown to bind an activating receptor TMIGD2. To explore the full potential of this axis inhibition, NextPoint Therapeutics is pursuing both B7-H7 and KIR3DL3 specific antibodies, is generating multiple approaches to enable tumor targeting and is approaching modulation of TMIGD2-mediated activity.


B7-H7/HHLA2 - A Novel Tumor-Associated Antigen for Tumor-Targeting Therapies

Strong overexpression of B7-H7 in tumor tissues with limited expression in normal tissues makes it an attractive target for tumor targeting approaches, which can be directed to the tumor via antibody-based binding to B7-H7. These include: targeted chemotherapies (antibody-drug conjugates), targeted radiotherapies, and T cell engagers.

B7-H7 staining in lung


B7-H7/HHLA2 - A potential biomarker to identify patients most likely to respond

High expression of B7-H7 on tumor cells and limited expression it normal tissues makes in an important potential biomarker for selection of patients most likely to respond to therapeutics targeting the B7-H7 checkpoint axis or directly targeting B7-H7.

We are developing an immunohistochemistry assay for detection of B7-H7 that will be used to select participants in clinical studies in addition to exploring integrated biomarker strategies to define optimal patient populations for different treatment approaches.


Designed to Reverse T and NK Cell Suppression

Our co-founders independently identified KIR3DL3 as the inhibitory receptor for B7-H7.

KIR3DL3 binding to B7-H7 interferes with the anti-tumor potential of T and NK cells and can contribute to tumor immune escape.

KIR3DL3 is upregulated on a subset of antigen-experienced, exhausted effector memory T cells, called TEMRA cells, and on a subpopulation of NK cells.

NPX267 is being studied in a phase 1 clinical trial in solid tumor malignancies known to express B7-H7.


Designed to block immunosuppression by KIR3DL3 while sparing immunostimulation by TMIGD2

NPX887 targets B7-H7 to block its interaction with KIR3DL3 and to prevent immunosuppression of T and NK cells

NPX887 enables the interaction of B7-H7 with its other ligand, TMIGD2, which can stimulate T and NK cell activation.

NPX887 has enhanced Fc receptor function to potentiate ADCC- mediated destruction of B7-H7-positive tumor cells

NPX887 is being studied in patients with solid tumor malignancies known to express B7-H7 in a phase 1 clinical trial.


NextPoint is developing a novel antibody-drug conjugate optimized to target B7-H7 on tumor cells.


NextPoint is developing a novel and potent T cell engager targeting B7-H7 which is designed to activate a tumor-directed immune response.

Clinical-Stage Project:

NPX267 is a first-in-class monoclonal antibody targeting KIR3DL3 which blocks the interaction with B7-H7 to re-activate T and NK cells. NPX267 is being studied in patients with solid tumor malignancies in a Phase 1 clinical trial.

Clinical-Stage Project:

NPX887 is an Fc-enhanced monoclonal IgG1 antibody that targets B7-H7 to block its immunosuppressive interaction with KIR3DL3 on T and NK cells while sparing the interaction with its stimulatory ligand, TMIGD2. NPX887 is being studied in patients with solid tumor malignancies in a phase 1 clinical trial.